English
Home > Products > CAS NO: 27696-12-4

China CAS NO: 27696-12-4 Factory

We've got a specialist, effectiveness staff to supply high quality service for our shopper. We always follow the tenet of customer-oriented, details-focused for CAS NO: 27696-12-4,CAS NO: 303-98-0,CAS NO: 40819-90-7,CAS NO: 60684-33-5,CAS NO: 65085-29-2, We are generally looking ahead to forming effective business associations with new clientele around the world.
CAS NO: 27696-12-4, Our company absorbs new ideas, strict quality control, a full range of service tracking, and adhere to make high-quality products. Our business aims to "honest and trustworthy, favorable price, customer first", so we won the trust of the majority of customers! If you are interested in our items and services, remember to do not hesitate to contact us!

Related Products

Hot Products

  • Benzhexol Hydrochloride

    Benzhexol Hydrochloride

    Product Name:Benzhexol Hydrochloride
    Molecular Weight:337.93
    CAS Registry Number:52-49-3
  • (9S)-9-Amino-9-deoxoerythromycin

    (9S)-9-Amino-9-deoxoerythromycin

    Product Name:(9S)-9-Amino-9-deoxoerythromycin
    Molecular Formula:C37H70N2O12
    Molecular Weight:734.96
    CAS Registry Number:26116-56-3
  • Strontium ranelate

    Strontium ranelate

    Product Name:Strontium ranelate
    Molecular Formula:C12H12N2O8SSr
    Molecular Weight;431.91
    CAS Registry Number;135459-87-9
  • Oxytocin

    Oxytocin

    Product Name:Oxytocin
    Molecular Formula:C43H66N12O12S2
    Molecular Weight;1007.19
    CAS Registry Number;50-56-6
  • Trometamol

    Trometamol

    Product Name:Trometamol
    Molecular Formula:C4H11NO3
    Molecular Weight:121.14
    CAS Registry Number:77-86-1 (83147-39-1)
  • 1,2,3,4-Tetrahydro-1-naphthoic acid

    1,2,3,4-Tetrahydro-1-naphthoic acid

    Product Name:1,2,3,4-Tetrahydro-1-naphthoic acid
    Molecular Formula:C11H12O2
    Molecular Weight:176.21
    CAS Registry Number:1914-65-4
  • Related Blog
  • Reviews

  • What are the raw materials required for pharmaceutical industry?

    Pharmaceutical industry has a lot of constraints and specialties which make it stand on a completely differents scale than any other industries. Being closely related to the medical field and also complementary to it, the pharmaceutical industry needs utmost care and precision in each and every aspect of the field ranging from collecting the raw materials to getting the final product ready for supply in the market.

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products...

  • What is Coenzyme Q10 CAS NO.303-98-0

    Coenzyme Q10 (CAS NO.303-98-0 ) is a fat-soluble antioxidant, which can activate the nutrition of human cells and cellular energy, and has the functions of improving human immunity, enhancing antioxidation, delaying ageing and enhancing human vitality.

  • Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

    Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

  • CAS No. 144689-24-7 Olmesartan Introduction

    Olmesartan is an angiotensin II receptor blocker, widely used for the treatment of hypertension. The Renin-Angiotensin-Aldosterone System (RAAS) plays an importent role in the development and progression of many diseases such as hypertension...

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept